Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Epirubicin × 1 year × Clear all

Phase

Status

Recruiting 10 Active not recruiting 10 Completed 5 Not yet recruiting 3 Terminated 2 Withdrawn 1 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 17 pembrolizumab 14 Specimen Handling 14 Cyclophosphamide 9 Biopsy 9 fludarabine 8 Radiotherapy 7 Nivolumab 6 Carboplatin 6 atezolizumab 5 Paclitaxel 5 venetoclax 4 niraparib 4 fludarabine phosphate 4 X-Rays 4 Radiosurgery 4 Phantoms, Imaging 4 Cisplatin 4 durvalumab 3 decitabine and cedazuridine drug combination 3 cemiplimab 3 avelumab 3 aldesleukin 3 Standard of Care 3 Radiation 3 Practice Guidelines as Topic 3 Ipilimumab 3 Injections 3 Gemcitabine 3 Fluorouracil 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06829199 2026-02-19

MK-5890-003

Merck Sharp & Dohme LLC

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡